Trial of aripiprazole in the treatment of first-episode schizophrenia

Hwa Young Lee, Byung-Joo Ham, Rhee Hun Kang, Jong Woo Paik, Sang Woo Hahn, Min-Soo Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims: Aripiprazole is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia. It is effective and well tolerated in patients with schizophrenia or schizoaffective disorder. The aim of the present study was to investigate therapeutic efficacy and tolerability of aripiprazole in patients with first-episode schizophrenia. Methods: Twenty-one patients meeting the DSM-IV criteria for schizophrenia were recruited. The Positive and Negative Symptom Scale (PANSS) and the Clinical Global Impressions Scale (CGI) were completed at the beginning of the study and again after 1, 2, 4, and 8 weeks of aripiprazole treatment. Side-effects were analyzed using the Udvalg for Kliniske Undersøgelser Side-Effect Rating Scale. Weight was checked at each testing session, and prolactin levels were measured at baseline and after 8 weeks of aripiprazole treatment. Results: Significant benefits were observed after the first week of treatment. After 1 week of aripiprazole treatment, subscale and total scores on the PANSS had decreased significantly. This significant decrease was maintained throughout the study period. The mean score of CGI severity was also significantly different after 2 weeks of aripiprazole administration when compared to baseline score, and the significance was maintained thereafter. Weight did not significantly change after aripiprazole administration. Although mean prolactin level was decreased at 8 weeks, the difference was not significant. Conclusions: Aripiprazole is an effective and well-tolerated antipsychotic agent in patients with first-episode schizophrenia. Further investigations with larger samples are needed.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalPsychiatry and Clinical Neurosciences
Volume64
Issue number1
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

Schizophrenia
Therapeutics
Prolactin
Antipsychotic Agents
Weights and Measures
Aripiprazole
Diagnostic and Statistical Manual of Mental Disorders
Psychotic Disorders

Keywords

  • Aripiprazole
  • Efficacy
  • First-episode schizophrenia
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Trial of aripiprazole in the treatment of first-episode schizophrenia. / Lee, Hwa Young; Ham, Byung-Joo; Kang, Rhee Hun; Paik, Jong Woo; Hahn, Sang Woo; Lee, Min-Soo.

In: Psychiatry and Clinical Neurosciences, Vol. 64, No. 1, 01.02.2010, p. 38-43.

Research output: Contribution to journalArticle

Lee, Hwa Young ; Ham, Byung-Joo ; Kang, Rhee Hun ; Paik, Jong Woo ; Hahn, Sang Woo ; Lee, Min-Soo. / Trial of aripiprazole in the treatment of first-episode schizophrenia. In: Psychiatry and Clinical Neurosciences. 2010 ; Vol. 64, No. 1. pp. 38-43.
@article{cb1fde3148bb4951acc8cdd55ac17a6c,
title = "Trial of aripiprazole in the treatment of first-episode schizophrenia",
abstract = "Aims: Aripiprazole is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia. It is effective and well tolerated in patients with schizophrenia or schizoaffective disorder. The aim of the present study was to investigate therapeutic efficacy and tolerability of aripiprazole in patients with first-episode schizophrenia. Methods: Twenty-one patients meeting the DSM-IV criteria for schizophrenia were recruited. The Positive and Negative Symptom Scale (PANSS) and the Clinical Global Impressions Scale (CGI) were completed at the beginning of the study and again after 1, 2, 4, and 8 weeks of aripiprazole treatment. Side-effects were analyzed using the Udvalg for Kliniske Unders{\o}gelser Side-Effect Rating Scale. Weight was checked at each testing session, and prolactin levels were measured at baseline and after 8 weeks of aripiprazole treatment. Results: Significant benefits were observed after the first week of treatment. After 1 week of aripiprazole treatment, subscale and total scores on the PANSS had decreased significantly. This significant decrease was maintained throughout the study period. The mean score of CGI severity was also significantly different after 2 weeks of aripiprazole administration when compared to baseline score, and the significance was maintained thereafter. Weight did not significantly change after aripiprazole administration. Although mean prolactin level was decreased at 8 weeks, the difference was not significant. Conclusions: Aripiprazole is an effective and well-tolerated antipsychotic agent in patients with first-episode schizophrenia. Further investigations with larger samples are needed.",
keywords = "Aripiprazole, Efficacy, First-episode schizophrenia, Tolerability",
author = "Lee, {Hwa Young} and Byung-Joo Ham and Kang, {Rhee Hun} and Paik, {Jong Woo} and Hahn, {Sang Woo} and Min-Soo Lee",
year = "2010",
month = "2",
day = "1",
doi = "10.1111/j.1440-1819.2009.02039.x",
language = "English",
volume = "64",
pages = "38--43",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Trial of aripiprazole in the treatment of first-episode schizophrenia

AU - Lee, Hwa Young

AU - Ham, Byung-Joo

AU - Kang, Rhee Hun

AU - Paik, Jong Woo

AU - Hahn, Sang Woo

AU - Lee, Min-Soo

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Aims: Aripiprazole is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia. It is effective and well tolerated in patients with schizophrenia or schizoaffective disorder. The aim of the present study was to investigate therapeutic efficacy and tolerability of aripiprazole in patients with first-episode schizophrenia. Methods: Twenty-one patients meeting the DSM-IV criteria for schizophrenia were recruited. The Positive and Negative Symptom Scale (PANSS) and the Clinical Global Impressions Scale (CGI) were completed at the beginning of the study and again after 1, 2, 4, and 8 weeks of aripiprazole treatment. Side-effects were analyzed using the Udvalg for Kliniske Undersøgelser Side-Effect Rating Scale. Weight was checked at each testing session, and prolactin levels were measured at baseline and after 8 weeks of aripiprazole treatment. Results: Significant benefits were observed after the first week of treatment. After 1 week of aripiprazole treatment, subscale and total scores on the PANSS had decreased significantly. This significant decrease was maintained throughout the study period. The mean score of CGI severity was also significantly different after 2 weeks of aripiprazole administration when compared to baseline score, and the significance was maintained thereafter. Weight did not significantly change after aripiprazole administration. Although mean prolactin level was decreased at 8 weeks, the difference was not significant. Conclusions: Aripiprazole is an effective and well-tolerated antipsychotic agent in patients with first-episode schizophrenia. Further investigations with larger samples are needed.

AB - Aims: Aripiprazole is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia. It is effective and well tolerated in patients with schizophrenia or schizoaffective disorder. The aim of the present study was to investigate therapeutic efficacy and tolerability of aripiprazole in patients with first-episode schizophrenia. Methods: Twenty-one patients meeting the DSM-IV criteria for schizophrenia were recruited. The Positive and Negative Symptom Scale (PANSS) and the Clinical Global Impressions Scale (CGI) were completed at the beginning of the study and again after 1, 2, 4, and 8 weeks of aripiprazole treatment. Side-effects were analyzed using the Udvalg for Kliniske Undersøgelser Side-Effect Rating Scale. Weight was checked at each testing session, and prolactin levels were measured at baseline and after 8 weeks of aripiprazole treatment. Results: Significant benefits were observed after the first week of treatment. After 1 week of aripiprazole treatment, subscale and total scores on the PANSS had decreased significantly. This significant decrease was maintained throughout the study period. The mean score of CGI severity was also significantly different after 2 weeks of aripiprazole administration when compared to baseline score, and the significance was maintained thereafter. Weight did not significantly change after aripiprazole administration. Although mean prolactin level was decreased at 8 weeks, the difference was not significant. Conclusions: Aripiprazole is an effective and well-tolerated antipsychotic agent in patients with first-episode schizophrenia. Further investigations with larger samples are needed.

KW - Aripiprazole

KW - Efficacy

KW - First-episode schizophrenia

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=75649144370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649144370&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.2009.02039.x

DO - 10.1111/j.1440-1819.2009.02039.x

M3 - Article

VL - 64

SP - 38

EP - 43

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 1

ER -